JAK2 Inhibition Impairs Proliferation and Sensitises Cervical Cancer Cells to Cisplatin-Induced Cell Death
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
JAK2 Inhibition Impairs Proliferation and Sensitises Cervical Cancer Cells to Cisplatin-Induced Cell Death
Authors
Keywords
-
Journal
Cancers
Volume 11, Issue 12, Pages 1934
Publisher
MDPI AG
Online
2019-12-05
DOI
10.3390/cancers11121934
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cervical intraepithelial neoplasia in women who had vaccination against HPV
- (2019) Giorgio Bogani et al. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
- Autocrine STAT3 activation in HPV positive cervical cancer through a virus-driven Rac1—NFκB—IL-6 signalling axis
- (2019) Ethan L. Morgan et al. PLoS Pathogens
- A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer and Systemic Inflammation
- (2018) Giuseppe Giaccone et al. Clinical Lung Cancer
- Targeting the IL-6/JAK/STAT3 signalling axis in cancer
- (2018) Daniel E. Johnson et al. Nature Reviews Clinical Oncology
- STAT3 activation by E6 is essential for the differentiation-dependent HPV18 life cycle
- (2018) Ethan L. Morgan et al. PLoS Pathogens
- Do STAT3 inhibitors have potential in the future for cancer therapy?
- (2017) Andrea L.A. Wong et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- HPV vaccines – A review of the first decade
- (2017) Diane M. Harper et al. GYNECOLOGIC ONCOLOGY
- STAT3 inhibition by WP1066 suppresses the growth and invasiveness of bladder cancer cells
- (2017) Yujiro Tsujita et al. ONCOLOGY REPORTS
- Modulation of the DNA damage response during the life cycle of human papillomaviruses
- (2017) Daniel C. Anacker et al. VIRUS RESEARCH
- KLF13 regulates the differentiation-dependent human papillomavirus life cycle in keratinocytes through STAT5 and IL-8
- (2016) W Zhang et al. ONCOGENE
- Molecular mechanisms of cisplatin resistance in cervical cancer
- (2016) Xueqiong Zhu et al. Drug Design Development and Therapy
- MiR-125a promotes paclitaxel sensitivity in cervical cancer through altering STAT3 expression
- (2016) Z Fan et al. Oncogenesis
- World Health Organization Guidelines for treatment of cervical intraepithelial neoplasia 2-3 and screen-and-treat strategies to prevent cervical cancer
- (2015) Nancy Santesso et al. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
- The Growing Epidemic of HPV-Positive Oropharyngeal Carcinoma: A Clinical Review for Primary Care Providers
- (2015) K. A. Moore et al. Journal of the American Board of Family Medicine
- Inhibition of the JAK/STAT pathway with ruxolitinib overcomes cisplatin resistance in non-small-cell lung cancer NSCLC
- (2014) Yuan Hu et al. APOPTOSIS
- IL-2 Enhances Cervical Cancer Cells Proliferation and JAK3/STAT5 Phosphorylation at Low Doses, While at High Doses IL-2 Has Opposite Effects
- (2014) Arturo Valle-Mendiola et al. CANCER INVESTIGATION
- The Role of STAT3 Signaling in Mediating Tumor Resistance to Cancer Therapy
- (2014) Fiona Tan et al. CURRENT DRUG TARGETS
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- STAT3 Target Genes Relevant to Human Cancers
- (2014) Richard Carpenter et al. Cancers
- The Arrival of JAK Inhibitors: Advancing the Treatment of Immune and Hematologic Disorders
- (2013) Yasuko Furumoto et al. BIODRUGS
- JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia
- (2013) W. Warsch et al. BLOOD
- Functional Regulatory Role of STAT3 in HPV16-Mediated Cervical Carcinogenesis
- (2013) Shirish Shukla et al. PLoS One
- The JAK-STAT Transcriptional Regulator, STAT-5, Activates the ATM DNA Damage Pathway to Induce HPV 31 Genome Amplification upon Epithelial Differentiation
- (2013) Shiyuan Hong et al. PLoS Pathogens
- STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia
- (2012) A. Jerez et al. BLOOD
- Reducing HPV-Associated Cancer Globally
- (2012) D. R. Lowy et al. Cancer Prevention Research
- The cell cycle regulator CDC25A is a target for JAK2V617F oncogene
- (2011) E.-F. Gautier et al. BLOOD
- The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors
- (2011) E. A. Nelson et al. BLOOD
- STAT3 Plays a Critical Role in KRAS-Induced Pancreatic Tumorigenesis
- (2011) R. B. Corcoran et al. CANCER RESEARCH
- Phosphorylation of p27Kip1 by JAK2 directly links cytokine receptor signaling to cell cycle control
- (2011) H Jäkel et al. ONCOGENE
- JAK2 V617F uses distinct signalling pathways to induce cell proliferation and neutrophil activation
- (2010) Seido Oku et al. BRITISH JOURNAL OF HAEMATOLOGY
- Inhibition of the JAK-2/STAT3 signaling pathway impedes the migratory and invasive potential of human glioblastoma cells
- (2010) Christian Senft et al. JOURNAL OF NEURO-ONCOLOGY
- Deregulation of STAT-5 isoforms in the development of HPV-mediated cervical carcinogenesis
- (2010) Ranbir C. Sobti et al. JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION
- Aberrant expression and constitutive activation of STAT3 in cervical carcinogenesis: implications in high-risk human papillomavirus infection
- (2010) Shirish Shukla et al. Molecular Cancer
- Human Papillomaviruses Activate the ATM DNA Damage Pathway for Viral Genome Amplification upon Differentiation
- (2009) Cary A. Moody et al. PLoS Pathogens
- STAT3 can be activated through paracrine signaling in breast epithelial cells
- (2008) Jacqueline C Lieblein et al. BMC CANCER
- Constitutive Activation of Signal Transducer and Activator of Transcription 5 Contributes to Tumor Growth, Epithelial-Mesenchymal Transition, and Resistance to Epidermal Growth Factor Receptor Targeting
- (2008) P. Koppikar et al. CLINICAL CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now